Clinical Trial Update: Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy [Phase 2]

View source ↗

Summary

This report covers a long-term, open-label Phase 2 safety study of LP352 in developmental and epileptic encephalopathy, including Dravet and Lennox-Gastaut synd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Developmental and Epileptic Encephalopathy
• Dravet Syndrome
• Lennox-gastaut Syndrome

Drugs mentioned

• LP352

Snippet

Sponsor: Longboard Pharmaceuticals | Conditions: Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 2 | Status: COMPLETED